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Background
Adoptive immunotherapy, including transfer of activated
NK cells, is currently under active investigation for
patients with refractory and relapsed acute myeloid leu-
kemia (AML). However, a highly immunosuppressive
microenvironment sustained in part by tumor-derived
exosomes, creates a major hurdle for adoptive immu-
notherapy. We recently reported that exosomes, virus-
size (30-100nm) membrane-bound vesicles, represent
one immunosuppressive mechanism operating in AML.
We found high levels of exosomes in plasma of newly-
diagnosed AML patients prior to any therapy. These
exosomes carried an immunosuppressive cargo, includ-
ing membrane-associated TGF-b1, PD-1, MICA/MICB
and markers of myeloid blasts. Infusion of activated NK
cells in patients with AML did not result in the expected
recovery of NK cell activity. We hypothesize that the pre-
sence of immunosuppressive plasma exosomes in refrac-
tory/relapsed AML patients may impair anti-tumor
activity of adoptive cell therapies.
Methods
Venous blood (20-50 mL) was obtained from patients with
refractory/relapsed AML (n=7). Exosome fractions were
isolated from the patients’ plasma and plasma of normal
controls by using mini-size exclusion chromatography
with Sepharose 2A. Protein levels, numbers and the size of
exosomes (qNano) and their morphology (transmission
electron microscopy) were determined. Exosomes were
characterized by Western blots for expression of exosome
markers, Tsg101 and CD81, and myeloid cell-surface mar-
kers associated with AML, interleukin-3 receptor alpha
chain (CD123) and C-type lectin-like molecule-1 (CLL-1),
CD44, CD96 and TGF-b1. Isolated normal human NK
cells were co-incubated with AML exosomes and multi-
parameter flow cytometry was used to monitor changes in
expression levels (mean fluorescence intensity) of NKG2D
on NK cells.
Results
Exosome fractions isolated from AML patients’ plasma
with refractory/relapsed AML had mean protein content
of 36 µg protein/mL plasma. AML exosomes contained
blast markers, CD123, CLL-1, CD44, CD96 suggesting
their leukemia origin. They were also enriched in TGF-b1,
which is known to interfere with NK cell activity and pro-
mote Treg expansion. Co-incubation of AML exosomes
with activated NK cells resulted in down-regulation of
NKG2D expression with a concomitant reduction of NK-
cell cytotoxicity. Antibody neutralization of TGF-b1 car-
ried by AML exosomes significantly abrogated their
immunosuppressive activity.
Conclusions
The persistently elevated levels of biologically-active
TGF-b1+ exosomes carrying leukemia blast markers in
plasma of refractory/relapsed AML patients indicate that
existing immune suppression will interfere with anti-leu-
kemia effects of adoptive cell therapies.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P60
Cite this article as: Boyiadzis et al.: Circulating exosomes carrying an
immunosuppressive cargo may interfere with adoptive cell therapies in
leukemia. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P60.
University of Pittsburgh, Pittsburgh, PA, USA
Boyiadzis et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P60
http://www.immunotherapyofcancer.org/content/3/S2/P60
© 2015 Boyiadzis et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
